尊敬的编辑老师您好你们发的定稿并不是我修改的那个稿件估计.DOCVIP

尊敬的编辑老师您好，你们发的定稿并不是我修改的那个稿件，估计定稿是编辑老师之前的初稿，还请老师按照这个稿件进修排版，谢谢 1 60mg/d与40mg/d相关问题，这系笔误，上一次已经改为60mg/d 2.其余没错，文中均对相关指标进行比较。手术相关指标主要指的是：对比剂用量、接触时间、水化量及旋磨例数。. 3.减少参考文献7条。 谢谢编辑老师 不同剂量阿托伐他汀联合水化预防冠脉介入术后造影剂肾病的临床研究 徐猛 许良兰 章福彬 孙磊 安徽省合肥市解放军第105医院 230000 [摘要] 目的：比较60mg/d与40mg/d阿托伐他汀分别联合水化预防急性心心肌梗死(AMI)患者冠脉介入术后造影剂肾病(CIN)的效果。方法：将2014年1月～2016年12月入选的172例AMI患者随机分为高剂量组（88例）与低剂量组（84例），在常规PCI治疗基础上，高剂量组患者入院后～术后72h口服60mg/d阿托伐他汀，低剂量组口服40mg/d阿托伐他汀，同时两组患者围术期均予静滴生理盐水水化治疗，记录两组手术指标、治疗前后生物学标志物及肾功能变化，比较两组CIN及临床不良事件发生率。结果：两组患者造影剂用量、接触时间、水化量及冠状动脉旋磨比例、平均每例患者支架植入数量差异均无统计学意义（P均＞0.05）。高剂量组术后3d ln(NT-proBNP)、hs-CRP、MMP-9较术前下降数值均显著高于低剂量组[(0.52±0.22 vs.0.37±0.17) pg/ml、(7.8±2.4 vs.6.3±1.9) mg/L、(27.5 ±9.5 vs.23.7±7.7) μg/L](P均＜0.05)。高剂量组术后3d Scr、BUN较术前升高数值与eGFR下降数值均显著低于低剂量组[(11.9±3.5 vs. 19.6±5.8)μmol/L、(1.53±0.52 vs. 2.38±0.65)mmol/L、(5.0±2.2 vs. 9.2±3.8)ml/min· 1.73m2] (P均＜0.05)。高剂量组术后CIN发生率、肾脏透析治疗比例均显著低于低剂量组[6.8% vs.16.7%、1.1% vs.8.3](P均＜0.05)。 结论：PCI围术期口服阿托伐他汀联合常规水化能预防CIN的发生，60mg/d的预防效果优于40mg/d。 [关键词]经皮冠状动脉介入术；造影剂肾病；阿托伐他汀；生物标志物；肾功能 Clinical study of different doses of Atorvastatin combined with hydration to prevent contrast induced nephropathy after percutaneous coronary intervention [Abstract] Objective: To compare the efficacy of hydration combined with 60mg/d or 40mg/d atorvastatin on prevention of contrast induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Methods: 172 AMI patients in January 2014 to December 2016 were randomly divided into high dose group (88 cases) and low dose group (84 cases), based on the conventional treatment of PCI, patients in high dose group after admission to 72h after PCI were given 60mg/d atorvastatin orally, while low dose group with 40mg/d atorvastatin orally, at the same time two group in the perioperative period were given intravenous saline water treatment, the operation associated indexes ,variations on biological markers and renal functi